- In late March 2026, Sarepta Therapeutics reported first-in-human Phase 1/2 data for its SRP-1001 and SRP-1003 siRNA programs in facioscapulohumeral muscular dystrophy type 1 and myotonic dystrophy type 1, showing dose-dependent muscle exposure, early biomarker effects and generally favorable tolerability using its avß6 integrin-targeted delivery platform.
- The early proof-of-concept knockdown of target protein or mRNA not only supports these rare disease programs, but also strengthens the case for Sarepta’s broader next-generation siRNA portfolio licensed from Arrowhead Pharmaceuticals across multiple neuromuscular and neurodegenerative indications.
- Next, we’ll examine how these early siRNA delivery and biomarker findings could influence Sarepta’s rare disease investment narrative and pipeline expectations.
AI is about to change healthcare. These 36 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
Sarepta Therapeutics Investment Narrative Recap
To own Sarepta today, you need to believe ELEVIDYS can overcome safety concerns and access bottlenecks while newer platforms expand beyond Duchenne. The SRP-1001 and SRP-1003 data modestly support the long term diversification story, but they do not change that near term sentiment and revenue are still most tied to ELEVIDYS safety, label evolution and site capacity, with regulatory scrutiny and operational delays remaining the key risks to watch.
Among recent updates, the ENDEAVOR Cohort 8 work to test prophylactic sirolimus with ELEVIDYS looks most relevant. While the siRNA results highlight a different modality, the biggest near term catalyst still rests on whether Sarepta can show regulators and physicians that enhanced immunosuppression meaningfully reduces acute liver injury risk in Duchenne patients, which could be critical for rebuilding confidence and unlocking more consistent gene therapy throughput across treatment centers.
Yet, against this promise of diversified platforms, investors should be aware of how ongoing safety scrutiny and site bottlenecks could still limit...
Read the full narrative on Sarepta Therapeutics (it's free!)
Sarepta Therapeutics' narrative projects $1.4 billion revenue and $100.2 million earnings by 2029. This requires a 13.3% yearly revenue decline and an earnings increase of about $813.6 million from -$713.4 million today.
Uncover how Sarepta Therapeutics' forecasts yield a $20.61 fair value, a 11% downside to its current price.
Exploring Other Perspectives
The most cautious analysts already assumed about US$2.9 billion of revenue and US$616.4 million of earnings by 2028, yet worry that safety scrutiny, capacity limits and high siRNA spending could still leave Sarepta short of those goals, reminding you that opinions can differ widely and this new SRP-1001 and SRP-1003 data may shift both the bullish and bearish cases over time.
Explore 7 other fair value estimates on Sarepta Therapeutics - why the stock might be worth 11% less than the current price!
Reach Your Own Conclusion
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Sarepta Therapeutics research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Sarepta Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Sarepta Therapeutics' overall financial health at a glance.
Ready For A Different Approach?
Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:
- Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 26 best rare earth metal stocks of the very few that mine this essential strategic resource.
- This technology could replace computers: discover 24 stocks that are working to make quantum computing a reality.
- We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com